obesity/inflammation

BACKGROUND OF THE INVENTION I. Field of the Invention The present invention relates generally to the fields of biology and medicine. More particularly, it concerns methods for the prevention and/or treatment of diseases, such as obesity, with antioxidant inflammation modulators (AIMs). II.

FIELD OF INVENTION A product for use in the treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimers disease and inflammatory bowel disease comprising at least one isolated bacterial strain from the species Prevotellaceae, herein the strain is

BACKGROUND OF THE INVENTION Diabetes and obesity affect numerous humans throughout the world, and are associated with or induces other diseases or conditions. In particular, diabetes and obesity are serious risk factors for diseases and conditions such as hypertension, gallbladder disease, cancer,

BACKGROUND OF THE INVENTION Diabetes and obesity affect numerous humans throughout the world, and are associated with or induces other diseases or conditions. In particular, diabetes and obesity are serious risk factors for diseases and conditions such as hypertension, gallbladder disease, cancer,

TECHNICAL FIELD The present invention relates to a PPAR gamma-specific monoclonal antibody, a hybridoma cell line producing the same, and a method for detecting a regulator related to diseases including inflammation, cancer and metabolic diseases, using the same. BACKGROUND ART The protein PPAR

FIELD OF THE INVENTION The invention relates to a probiotic and a composition comprising the same. Particularly, the invention relates to a new lactic acid bacteria and its use in enhancing immunomodulatory and anti-inflammatory activity. BACKGROUND OF THE INVENTION Fermented food products contain

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 5, 2018, is named P224214US_WO_ST25_3429641.txt and is 858 bytes in size. FIELD OF

The present invention relates to the field of bioorgmic chemistry and concerns N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof, novel processes for synthesis of said compounds as well as pharmaceutical compositions based on them and use thereof in medicine as

The present invention relates to the field of bioorganic chemistry and concerns N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof, novel processes for synthesis of said compounds as well as pharmaceutical compositions based on them and use thereof in medicine as

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/007905, filed Dec. 29, 2009, which claims benefit of Korean Patent Application 10-2009-0022937, filed Mar. 18, 2009. TECHNICAL FIELD The

The present invention relates to 1,4-disubstituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals. Neuropeptide Y (NPY), first isolated

FIELD OF INVENTION The invention in general relates to medicaments for obesity management. More specifically, it relates to anti-obesity potential of Calebin A. DESCRIPTION OF PRIOR ART Obesity is the most prevalent nutritional disorder in industrialized countries and is a growing problem in

FIELD OF INVENTION The invention in general relates to medicaments for obesity management. More specifically, it relates to anti-obesity potential of Calebin A. DESCRIPTION OF PRIOR ART Obesity is the most prevalent nutritional disorder in industrialized countries and is a growing problem in

REFERENCE TO SEQUENCE LISTING IDENTIFICATION The Sequence Listing, which is a part of the present disclosure, includes a computer readable file "RUC.sub.--112WO_ST25.txt" generated by U.S. Patent & Trademark Office PatentIn version 3.5 software comprising nucleotide and/or amino acid sequences

FIELD OF THE INVENTION The instant invention is concerned with acyl sulfamides and pharmaceutically acceptable salts and prodrugs thereof and their use as therapeutic. compounds, particularly in the treatment of obesity, of Type 2 diabetes mellitus (often referred to as non-insulin dependent